Related Experiment Video

Updated: Aug 10, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Effects of Ruxolitinib on Myeloproliferative Neoplasms via the Negative Regulators

Su-Yun Wang, Xu-Lei Xie, Jia-Yi Liang

    Clinical Laboratory
    |February 14, 2023
    PubMed
    Abstract

    Insights

    This study investigated the JAK/STAT pathway in myeloproliferative neoplasms (MPNs). Ruxolitinib treatment altered JAK2, SOCS-1, and SHP-1 expression, impacting cell apoptosis and viability in human erythroleukemia cells.

    Area of Science:

    • Hematology
    • Molecular Biology
    • Oncology

    Background:

    • Myeloproliferative neoplasms (MPNs) are characterized by the JAK2V617F mutation.
    • The JAK/STAT pathway plays a crucial role in MPN pathogenesis.
    • Understanding the expression of JAK2, SOCS-1, and SHP-1 is vital in MPN research.

    Purpose of the Study:

    • To evaluate JAK2V617F mutation and p-JAK2, SOCS-1, SHP-1 expression in MPN patients.
    • To investigate the role of the JAK/STAT pathway in human erythroleukemia (HEL) cells with JAK2V617F mutation.
    • To assess the therapeutic effect of ruxolitinib on HEL cells.

    Main Methods:

    • Immunohistochemical staining of bone marrow biopsies to detect protein expression.
    • Flow cytometry and Caspase 3/7 assay kits to analyze cell apoptosis and cell cycle.
    • Evaluation of JAK2, SOCS1, and SHP1 mRNA and protein expression in HEL cells treated with ruxolitinib.

    Main Results:

    • Significant differences in p-JAK2, SOCS-1, and SHP-1 expression were observed between MPN patients and controls (p < 0.01).
    • Treatment with ruxolitinib significantly affected HEL cell viability, apoptosis, and caspase activity.
    • Ruxolitinib treatment led to decreased JAK2 and p-JAK2 expression and increased SOCS1 and SHP1 expression in HEL cells (p < 0.01).

    Conclusions:

    • The JAK/STAT pathway is significantly altered in JAK2V617F-positive MPNs.
    • Ruxolitinib demonstrates therapeutic potential by modulating JAK/STAT signaling, inducing apoptosis, and reducing viability in HEL cells.
    • Expression levels of JAK2, SOCS-1, and SHP-1 are key indicators in MPN and response to therapy.

    More Related Videos

    Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

    Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

    Published on: February 21, 2018

    10.0K
    Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

    Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

    Published on: May 15, 2019

    13.3K

    Related Concept Videos

    Negative Regulator Molecules01:23

    Negative Regulator Molecules

    Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
    35.5K
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    4.6K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    3.8K
    Receptor Downregulation in MVBs01:15

    Receptor Downregulation in MVBs

    Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
    The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
    2.1K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    4.9K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.8K